Hangzhou Biotest Biotech Co Ltd (688767) - Net Assets
Based on the latest financial reports, Hangzhou Biotest Biotech Co Ltd (688767) has net assets worth CN¥2.36 Billion CNY (≈ $345.97 Million USD) as of March 2026. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (CN¥2.49 Billion ≈ $363.78 Million USD) and total liabilities (CN¥121.73 Million ≈ $17.81 Million USD). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. For live market cap and overall valuation, see 688767 market cap.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | CN¥2.36 Billion |
| % of Total Assets | 95.1% |
| Annual Growth Rate | 52.84% |
| 5-Year Change | 12.48% |
| 10-Year Change | N/A |
| Growth Volatility | 135.29 |
Hangzhou Biotest Biotech Co Ltd - Net Assets Trend (2017–2025)
This chart illustrates how Hangzhou Biotest Biotech Co Ltd's net assets have evolved over time, based on quarterly financial data.
Annual Net Assets for Hangzhou Biotest Biotech Co Ltd (2017–2025)
The table below shows the annual net assets of Hangzhou Biotest Biotech Co Ltd from 2017 to 2025. See Hangzhou Biotest Biotech Co Ltd net asset quality index to measure how much of total assets are equity-financed.
| Year | Net Assets | Change |
|---|---|---|
| 2025-12-31 | CN¥2.37 Billion ≈ $346.99 Million |
-1.70% |
| 2024-12-31 | CN¥2.41 Billion ≈ $353.00 Million |
-0.35% |
| 2023-12-31 | CN¥2.42 Billion ≈ $354.23 Million |
-5.52% |
| 2022-12-31 | CN¥2.56 Billion ≈ $374.94 Million |
+21.54% |
| 2021-12-31 | CN¥2.11 Billion ≈ $308.49 Million |
+375.85% |
| 2020-12-31 | CN¥443.02 Million ≈ $64.83 Million |
+251.75% |
| 2019-12-31 | CN¥125.95 Million ≈ $18.43 Million |
+28.32% |
| 2018-12-31 | CN¥98.15 Million ≈ $14.36 Million |
+23.26% |
| 2017-12-31 | CN¥79.63 Million ≈ $11.65 Million |
-- |
Equity Component Analysis
This analysis shows how different components contribute to Hangzhou Biotest Biotech Co Ltd's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have grown by 143933753750.0% over the analyzed period, indicating profitable operations and earnings retention.
Current Equity Component Breakdown (December 2025)
| Component | Amount | Percentage |
|---|---|---|
| Retained Earnings | CN¥1.43 Billion | 60.19% |
| Other Components | CN¥943.53 Million | 39.81% |
| Total Equity | CN¥2.37 Billion | 100.00% |
Hangzhou Biotest Biotech Co Ltd Competitors by Market Cap
The table below lists competitors of Hangzhou Biotest Biotech Co Ltd ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Yangmei Chemical Co Ltd
SHG:600691
|
$890.06 Million |
|
Santacruz Silver Mining Ltd.
V:SCZ
|
$890.25 Million |
|
Mesnac Co Ltd
SHE:002073
|
$890.40 Million |
|
Sparebanken Sor
OL:SOR
|
$890.43 Million |
|
Chengdu Hongqi Chain Co Ltd
SHE:002697
|
$889.58 Million |
|
CAP S.A
SN:CAP
|
$889.32 Million |
|
Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co Ltd
SHG:688505
|
$888.81 Million |
|
Zhejiang Tony Electronic Co Ltd
SHG:603595
|
$888.78 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Hangzhou Biotest Biotech Co Ltd's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from 2,409,476,107 to 2,369,789,815, a change of -39,686,292 (-1.6%).
- Net income of 46,795,700 contributed positively to equity growth.
- Dividend payments of 159,875,000 reduced retained earnings.
- Other comprehensive income decreased equity by 939,567.
- Other factors increased equity by 74,332,575.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | CN¥46.80 Million | +1.97% |
| Dividends Paid | CN¥159.88 Million | -6.75% |
| Other Comprehensive Income | CN¥-939.57K | -0.04% |
| Other Changes | CN¥74.33 Million | +3.14% |
| Total Change | CN¥- | -1.65% |
Book Value vs Market Value Analysis
This analysis compares Hangzhou Biotest Biotech Co Ltd's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 2.51x
- The company is trading above its book value, indicating the market recognizes value beyond its reported assets.
- The price-to-book ratio has decreased from 56.83x to 2.51x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2017-12-31 | CN¥0.72 | CN¥40.72 | x |
| 2018-12-31 | CN¥0.88 | CN¥40.72 | x |
| 2019-12-31 | CN¥1.13 | CN¥40.72 | x |
| 2020-12-31 | CN¥3.97 | CN¥40.72 | x |
| 2021-12-31 | CN¥17.37 | CN¥40.72 | x |
| 2022-12-31 | CN¥17.14 | CN¥40.72 | x |
| 2023-12-31 | CN¥16.18 | CN¥40.72 | x |
| 2024-12-31 | CN¥16.35 | CN¥40.72 | x |
| 2025-12-31 | CN¥16.21 | CN¥40.72 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Hangzhou Biotest Biotech Co Ltd utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 1.97%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 10.44%
- • Asset Turnover: 0.18x
- • Equity Multiplier: 1.07x
- Recent ROE (1.97%) is below the historical average (25.28%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2017 | 5.02% | 3.31% | 0.95x | 1.59x | CN¥-3.99 Million |
| 2018 | 19.12% | 10.49% | 1.17x | 1.56x | CN¥9.02 Million |
| 2019 | 22.23% | 13.52% | 0.99x | 1.66x | CN¥15.53 Million |
| 2020 | 97.98% | 50.28% | 1.37x | 1.43x | CN¥390.73 Million |
| 2021 | 39.56% | 45.85% | 0.75x | 1.15x | CN¥622.88 Million |
| 2022 | 30.21% | 40.69% | 0.69x | 1.07x | CN¥517.51 Million |
| 2023 | 4.41% | 24.11% | 0.17x | 1.07x | CN¥-134.92 Million |
| 2024 | 7.04% | 30.30% | 0.21x | 1.08x | CN¥-71.43 Million |
| 2025 | 1.97% | 10.44% | 0.18x | 1.07x | CN¥-190.18 Million |
Industry Comparison
This section compares Hangzhou Biotest Biotech Co Ltd's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $2,039,335,856
- Average return on equity (ROE) among peers: 12.92%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Hangzhou Biotest Biotech Co Ltd (688767) | CN¥2.36 Billion | 5.02% | 0.05x | $889.82 Million |
| Shenzhen CAU Technology Co Ltd (000004) | $105.51 Million | 6.20% | 2.16x | $9.88 Million |
| Pacific Shuanglin Bio pharmacy Co Ltd (000403) | $599.28 Million | 18.21% | 0.97x | $1.48 Billion |
| Nanhua Bio Medicine Co Ltd (000504) | $423.50 Million | 7.52% | 0.41x | $407.11 Million |
| Jiangsu Sihuan Bioengineering Co Ltd (000518) | $675.54 Million | 1.08% | 0.38x | $572.49 Million |
| Chengzhi Shareholding Co Ltd (000990) | $2.62 Billion | 5.26% | 0.88x | $1.59 Billion |
| Hualan Biological EngineeringInc (002007) | $1.86 Billion | 32.78% | 0.08x | $3.52 Billion |
| Da An Gene Co Ltd of Sun Yat-Sen University (002030) | $50.50 Million | 27.90% | 0.97x | $1.15 Billion |
| Shanghai RAAS Blood Products Co Ltd Class A (002252) | $11.49 Billion | 5.29% | 0.03x | $4.65 Billion |
| Baolingbao Biology Co Ltd (002286) | $817.45 Million | 8.40% | 0.36x | $438.15 Million |
| Tibet Cheezheng Tibetan Medicine Co Ltd (002287) | $1.75 Billion | 16.55% | 0.19x | $1.66 Billion |
About Hangzhou Biotest Biotech Co Ltd
Hangzhou Biotest Biotech Co.,Ltd. engages in the research and development, manufacture, sale, and service of in vitro diagnostic assays and reagents, and instruments in China and internationally. The company offers medical test products for fertility health, cardiology, oncology, inflammation, veterinary test, drug of abuse, infectious diseases, and other diagnostic rapid test. It also provides m… Read more